首页> 外文期刊>Journal of Clinical Pharmacy and Therapeutics >Adverse drug reactions during hepatitis C treatment with direct‐acting antivirals: The role of medication errors, their impact on treatment discontinuation and their preventability. New insights from the Campania Region (Italy) spontaneous reporting system
【24h】

Adverse drug reactions during hepatitis C treatment with direct‐acting antivirals: The role of medication errors, their impact on treatment discontinuation and their preventability. New insights from the Campania Region (Italy) spontaneous reporting system

机译:对丙型肝炎治疗过程中的不良药物反应,直接作用抗病毒药物:药物误差的作用,它们对治疗中断的影响及其预防性。 坎帕尼亚地区(意大利)自发报告系统的新见解

获取原文
获取原文并翻译 | 示例
           

摘要

Summary What is known and Objective Medication errors, such as unnecessary treatment discontinuation during treatment with direct‐acting antivirals ( DAA s), can lead to imbalances in the benefit‐to‐risk ratio. This risk is especially high when the medication error leads to adverse drug reactions ( ADR s). However, to date, evidence on the frequency of this phenomenon is scarce. This study aims to provide better insight into ADR s possibly due to medication errors leading to DAA discontinuation and their preventability. Methods The Italian Pharmacovigilance Network database was used to extract individual case safety reports ( ICSR s) generated from July 2012 to March 2017 via the Campania Region (Italy) spontaneous reporting system. ICSR s that included ledipasvir/sofosbuvir, ombitasvir/paritaprevir/ritonavir, dasabuvir, daclatasvir, sofosbuvir, simeprevir or elbasvir/grazoprevir as suspected drugs were included in this study. A preventability assessment was then performed utilizing the “P‐Method,” an algorithm that evaluates known risk factors due to medication errors that can be detected in ICSR s. Results and discussion Of the 355 cases included in this study, 6 (1.69%) were classified as preventable and 52 (14.6%) were classified as potentially preventable. The most frequently identified critical criteria (risk factor) for preventable or potentially preventable cases were drug‐drug interactions and incorrect drug dosing as part of the antiviral treatment scheme. In total, 89 of the 355 cases (25.1%) discontinued use of the DAA s due to ADR s, of which 20 of the 89 cases (22.5%) were due to an unimportant medical event as classified by the European Medicine Agency important medical event list. What is new and Conclusion This study found a proportion of preventable/potentially preventable ADR s involving DAA , which could be improved in the Campania Region (Italy). Additionally, the study identified a high proportion of seemingly unnecessary DAA discontinuations among patients who experienced ADR s.
机译:发明内容有哪些已知的和客观的药物误差,例如在用直接作用抗病毒(DAA S)处理期间不必要的治疗停止,可以导致受益于风险比率的不平衡。当药物误差导致不良药物反应(ADRS)时,这种风险特别高。然而,迄今为止,关于这种现象的频率的证据是稀缺的。本研究旨在由于导致导致DAA中断及其预防性的药物错误,可能会更好地了解ADR S。方法采用意大利药所网络数据库,通过坎帕尼亚地区(意大利)自发报告系统提取从2012年7月至2017年3月生成的单个案例安全报告(ICSRS)。 ICSR S包括LEDIPASVIR / SOFOSBUVIR,OMBITASVIR / PARITAPREVIR / RITONAVIR,DASBUVIR,DACLATASVIR,SOFOSBUVIR,SIMEPREVIR或ELBASVIR / Grazogrevir作为疑似药物纳入本研究。然后利用“p-方法”进行预防性评估,该算法评估由于可以在ICSR S中检测的药物误差引起的已知风险因素。结果和讨论本研究中包含的355例,6(1.69%)被归类为可预防,52名(14.6%)被归类为潜在预防。可预防或潜在可预防的病例的最常确定的关键标准(风险因素)是药物 - 药物相互作用和作为抗病毒治疗方案的一部分的药物剂量不正确。总共有89例(25.1%)由于ADR S停止使用DAA S,其中89例中的20例(22.5%)是由于欧洲医学机构归类的不重要的医疗活动活动列表。什么是新的和结论本研究发现了涉及DAA的可预防/潜在可预防的ADR的比例,这可以在Campania地区(意大利)得到改善。此外,该研究确定了经历ADR S的患者的看似不必要的DAA中断的高比例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号